Endoscopic therapy of bleeding peptic ulcers: a cost-benefit analysis.
Endoscopic hemostatic therapies have become increasingly popular and appear capable of controlling hemorrhage from peptic ulcers and reducing the need for surgery, but many physicians are unsure that the efficacy justifies the cost. In order to study this clinically and economically important issue, we developed a mathematical model to analyze the economics of endoscopic therapy of bleeding peptic ulcers. Endoscopic therapy appears capable of reducing direct hospital costs only when selectively applied to those patients with the highest risk of requiring surgery. Sensitivity analysis identifies efficacy, treatment cost, and the rebleeding rate in untreated patients as the most critical variables affecting the cost of interventional endoscopy. Using neodymium: YAG laser photocoagulation as an example, interventional endoscopy can be cost-effective for treating selected patients with bleeding peptic ulcers. Should other hemostatic devices such as the heater probe and bipolar electrocoagulator prove to be as effective as the laser, even greater cost savings could be achieved.
D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004724:Endoscopy / Q000191:economics*; D006801:Humans; D008028:Light Coagulation / Q000191:economics*; D008962:Models, Theoretical; D010438:Peptic Ulcer Hemorrhage / Q000191:economics / Q000601:surgery*